News Archives - Page 18 of 40

We are very honoured to count LFB among the Sponsors of BioFIT 2018

Many thanks to LFB for joining BioFIT 2018 as a Contributing Sponsor!

Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare. The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.

The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.

LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries. Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients. Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.

Join key BioFIT 2018 sponsors such as Bayer, Roche, MSD, Boehringer Ingelheim, Pfizer and VIB, to have the opportunity to:

Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count LFB among the Sponsors of BioFIT 2018 Read More »

#BioFIT 2018 preliminary programme is available!

News / Valentine Delabie

#BioFIT2018 preliminary programme is now available

In this brochure, you will find all the information you need about the 7^th edition of the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation in the field of Life Sciences.

Download the preliminary programme

#BioFIT 2018 preliminary programme is available! Read More »

Apply to the Licensing Opportunity Presentations

News / Valentine Delabie

Are you a tech transfer with a ready-to-be-licensed technology?

Apply to the presentation sessions to:

Promote your innovations
Receive a speed-monitoring from pharma, biotech, TTO and investors
Find partners who could support your project

1. Apply
Dedicated to TTO, universities or related structures that have ready-to-be-licensed technologies

2. Be selected
A jury of experts will select the most innovative projects

3. Exhibit
The selected candidates will benefit from a poster’s exhibition at bioFIT describing their out-licensing opportunities

4. Pitch
Presentations of the selected projects to potential industrial partners during BioFIT

5. Find partners
The presenters can easily find industrial partners who could in-license their assets

Apply to the Licensing Opportunity Presentations

Apply to the Licensing Opportunity Presentations Read More »

Conference Insight

News / Valentine Delabie

Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

4 Dec 2018 9:30 – 11:00 am

The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.[/vc_column_text][vc_column_text]They will share their experience:

Jan Adams, Managing Director, EMBL Ventures (DE)
Jonathan Tobin, Investment Director, Arix Bioscience (UK)

Discover the BioFIT 2018 conference programme

Conference Insight Read More »

They will speak at BioFIT 2018!

News / Valentine Delabie

Discover the new speakers that will share their vision at BioFIT 2018:

Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.

Alain Chevallier
Life Sciences Partner
Truffle Capital

Marco A. Chacon
Assistant Vice President of Industry Alliances
University of Maryland Baltimore

Rodolphe Besserve
Head SuFT Advisory, Start-up & French Techs
Société Générale Corporate Investments and Banking

Zishan Haroon
Chairman and General Partner
JulzCo

Discover all the confirmed speakers

Discover the BioFIT 2018 conference programme

They will speak at BioFIT 2018! Read More »

Apply to the Start-up Slams

News / Valentine Delabie

Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)?

Apply to the presentation sessions to:

Promote your innovations
Receive a speed-monitoring from pharma, biotech, TTO and investors
Find partners who could support your project

1. Apply before 30^th June
Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)

2. Be selected
A jury of experts will select the most innovative projects

3. Exhibit
The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings

4. Pitch
A 6-7 minute presentation of each selected project to potential partners and investors during BioFIT

5. Receive a speed-mentoring
A jury composed of pharma and investors will give feedback and advice to the presenters

6. Be awarded
The most innovative start-up will be awarded by the jury of experts of BioFIT

Apply to the Start-up Slams

Apply to the Start-up Slams Read More »

Conference Insight

News / Valentine Delabie

5 Dec 2018 9:00 – 10:30 am

When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?

They will share their experiences:

Adrian Ibrahim, Head of technology Transfer, Wellcome Sanger Institute (UK)
Caroline Barelle, CEO, Elasmogen (UK)
Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
Steven J. Klein, Vice President, Business Development IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research (CA)

Discover the BioFIT 2018 conference programme

Conference Insight Read More »

Discover the BioFIT 2018 preliminary conference programme!

News / Nadège Joly

The BioFIT Steering Committee is glad to announce the BioFIT 2018 preliminary conference programme:

PLENARY SESSION: Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

TRACK 1: Best practices in academia-industry R&D collaborations

Artificial Intelligence to speed-up drug discovery: The revolutionary road to advance innovation.
A prospective overview of the forthcoming cross-sectorial collaborations and licensing deals between human and animal health
Beyond shared means, common strategies to collectively succeed
Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

Interested in joining a panel?

TRACK 2: Nurturing and licensing early-stage assets

What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
An overview of the recent joint initiatives to derisk academic-origin assets
Questioning TTOs financing models: Could their expected financial outcome bias the tech transfer process?
Under pressure: How does the urge to bring rare disease therapies create a new range of business models or collaborative models?

Interested in joining a panel?

TRACK 3: Early-stage innovation: Identify the right funding sources

Are philanthropic and alternative sources of soft funding always a free lunch?
Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very initial stage?
Are immunotherapies a new investment Eldorado?
Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

Interested in joining a panel?

Discover the BioFIT 2018 preliminary conference programme! Read More »